Bill Gates' Investment Firm Takes Stake in Schrödinger

Schrödinger said that the investment will allow it to pursue several research and development projects "with the aim of making considerable improvements in the state of the art in computer-aided drug design."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.